Physician profile
Parul Garg Pathak
NPI 1265424212
$2,974.00
in general payments reported to CMS, 2019-2025
38 companies · $492 in 2025
The $492 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $35.46 · 2021: $248 · 2022: $386 · 2023: $725 · 2024: $779 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,995.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $430.60 | 2021-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $221.34 | 2021-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Ironshore Pharmaceuticals INC. | $210.57 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $179.30 | 2019-2024 | Strensiq |
| Glaxosmithkline, LLC. | $156.88 | 2019-2023 | Pediarix, Bexsero, Rotarix |
| Tris Pharma INC | $144.69 | 2019-2024 | Dyanavel Xr |
| Tolmar, INC. | $136.22 | 2023-2025 | Fensolvi |
| Sanofi-Aventis U.S. LLC | $130.82 | 2024-2025 | |
| Sanofi Pasteur INC. | $102.85 | 2021-2023 | |
| Alk-Abello, INC | $91.21 | 2025 | Neffy, Odactra, Grastek |
| Seqirus USA INC | $86.69 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent, Fluad Quadrivalent |
| Kyowa Kirin, INC. | $86.63 | 2023-2025 | Crysvita |
| Azurity Pharmaceuticals, INC. | $86.19 | 2023-2024 | Triptodur, Triptodur |
| Astrazeneca Pharmaceuticals LP | $83.20 | 2021-2024 | Flumist Quadrivalent |
| Ascendis Pharma Endocrinology INC | $75.71 | 2023-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $69.27 | 2019-2024 | |
| Dexcom, INC. | $67.88 | 2021-2024 | Dexcom G6 Transmitter |
| Vertical Pharmaceuticals, LLC | $61.39 | 2019 | |
| Sobi, INC | $55.78 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $53.29 | 2021-2024 | Gvoke Hypopen |
| Ultragenyx Pharmaceutical INC. | $49.19 | 2022-2024 | Crysvita |
| Lilly USA, LLC | $44.37 | 2019-2023 | Baqsimi |
| Biomarin Pharmaceutical INC. | $42.16 | 2024-2025 | Voxzogo 1.2mg |
| Neurelis, INC. | $34.13 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $33.34 | 2024 | |
| Zealand Pharma US, INC. | $32.47 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.19 | 2020-2021 | |
| Biomerieux INC | $25.00 | 2025 | |
| Pfizer INC. | $19.22 | 2023 | |
| Collegium Pharmaceutical, INC. | $18.67 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $16.54 | 2021 | |
| Tandem Diabetes Care, INC. | $15.55 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Tolmar Pharmaceuticals, INC. | $15.52 | 2022 | |
| Phadia US INC. | $15.45 | 2023 | Immunocap |
| Neos Therapeutics, LP | $14.32 | 2019 | |
| Adlon Therapeutics L.P. | $14.22 | 2019 | |
| Cepheid | $13.86 | 2025 | Genexpert |
| Genentech USA, INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parul Pathak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.